Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Calobrace

Plastic Surgery Louisville, KY Medical Doctor

NPI 1144597741 CMS profile 6378

2341 Lime Kiln Ln, Louisville, KY 40222

Open in the dashboard

General payments

$574,423

519 records reported · program years 2019–2025

Research payments

$38,150

Paid to them · 84 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Calobrace of Louisville, KY is reported in the CMS Open Payments database as having received $574,423 across 519 general payments and $38,150 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,354 77
2024 General $7,671 36
2023 General $165,959 89
2022 General $322,374 110
2022 Research $13,750 1
2021 General $18,228 84
2021 Research $7,250 1
2020 General $10,317 59
2020 Research $4,000 1
2019 General $21,521 64
2019 Research $13,150 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Calobrace
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Michael Calobrace were reported at $28,354. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Michael Calobrace Plastic Surgery median Middle half National median
2019 $21,521 $371 $122–$1,483 $163
2020 $10,317 $158 $52–$438 $114
2021 $18,228 $249 $87–$752 $132
2022 $322,374 $274 $102–$793 $149
2023 $165,959 $299 $113–$891 $160
2024 $7,671 $361 $124–$1,062 $164
2025 $28,354 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Surgical Innovation Associates, Inc. $307,570 2 payments
  2. AbbVie, Inc. $124,290 39 payments
  3. Sientra, Inc. $74,767 111 payments
  4. Motiva USA, LLC $30,758 52 payments
  5. Allergan Inc. $14,997 103 payments
  6. Merz North America, Inc. $8,251 48 payments
  7. Galderma Laboratories, L.P. $3,890 52 payments
  8. Davol Inc. $3,463 39 payments
  9. Mentor Worldwide LLC $3,196 23 payments
  10. Tepha Inc $1,200 16 payments
  11. Other $2,041 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $306,930 1 payment
  2. Grant $123,600 1 payment
  3. Consulting Fee $57,712 21 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,900 8 payments
  5. Food and Beverage $31,175 476 payments
  6. Travel and Lodging $18,379 10 payments
  7. Long term medical supply or device loan $640 1 payment
  8. Gift $87 1 payment
Products named General payments · program years 2019–2025
  1. DuraSorb Monofilament Mesh $307,570 2 payments
  2. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $74,767 111 payments
  3. Motiva Implant Matrix Devices $27,344 42 payments
  4. NATRELLE SALINE-FILLED BREAST IMPLANTS $5,794 18 payments
  5. REVOLVE $4,728 4 payments
  6. BOTOX COSMETIC $4,374 13 payments
  7. BOTOX $3,505 36 payments
  8. Motiva Implant Matrix Plastic Surgery $3,103 6 payments
  9. MENTOR MemoryGel Resterilizable Gel Sizer $3,062 22 payments
  10. Xeomin $2,327 12 payments
  11. Other $10,317 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sientra, Inc. $38,150 84 payments

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

184

Median for Plastic Surgery: 39

Drug cost

$2,420

Median for Plastic Surgery: $219

Branded share of claims

48.4%

Median for Plastic Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clonidine Generic 23 $864
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 48 $559
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 15 $483
Cephalexin Generic 40 $188
Erythromycin Erythromycin Base Brand 11 $101
Ciprofloxacin Hcl Generic 21 $93
Ondansetron Odt Ondansetron Brand 15 $85
Doxycycline Monohydrate Generic 11 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 700 Part D prescribers listed as Plastic Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
$349 — —
BOTOX
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

603 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record